|
|||||||||
|
|
|
|
|
|
|
|
|
|
|
NEOPLASIA
From the Department of Medical Biochemistry, Graduate
School of Medical Sciences, Kyushu University, and the First Department
of Pathology, Fukuoka University School of Medicine, Fukuoka, Japan,
and Nikken Chemicals Co Ltd, Oomiya Research Laboratory, Oomiya, Japan.
To understand the molecular basis for multidrug-resistant (MDR)
cancer cells in vivo, this study analyzed molecular changes of
the mdr1a gene region in leukemia cells in mice
during continuous treatment with vincristine. An inverse
insertion of murine leukemia retrovirus (MuLV) into the
5'-flanking region of the mdr1a gene was found.
This insertion was concomitantly accompanied by up-regulation of the
mdr1a gene and the loss of chemosensitivity. Deletion of long-terminal repeat (LTR) sequences dramatically decreased the mdr1a promoter-driven reporter activity. The MuLV LTR
insertion appears to exert its enhancer activity on
mdr1a transcription during the appearance of MDR leukemia
cells. Two mechanisms were postulated to explain the mdr1a
gene activation by retrovirus insertion during in vivo chemotreatment:
de novo insertion of MuLV induced by vincristine treatment and
selection of a small fraction of pre-existing cells carrying MuLV
insertion during vincristine treatment. No rearranged sequence was
detected by polymerase chain reaction in parental cells. This result
argued for the first mechanism. The randomly altered distribution of MuLV during repetitive chemotreatment might also be consistent with
this hypothesis. On the other hand, the retrovirus insertion was
detected at the same site of the mdr1a promoter region in 2 independent experiments, which suggests the second mechanism. It should
be noted that in vivo chemotreatment using vincristine could generate
the mdr1a-overexpressing cells through retrovirus insertion
and the enhancer effect of the LTR.
(Blood. 2001;97:759-766) The acquisition of a multidrug-resistant (MDR)
phenotype in cancer cells is often associated with increased expression
of the cellular surface P-glycoprotein (P-gp), which functions as an
energy-dependent drug efflux pump, thereby resulting in a decrease of
drug concentrations within cells.1-3 Expression of P-gp in various malignancies might become one of the major obstacles to chemotherapy, especially in hematopoietic malignancies.4-6
Mammalian P-gps are encoded by small families of genes known as linked
MDR genes, of which there are 2 known members in humans
(PGY1 and PGY3, also known as MDR1 and
MDR3, respectively)3,7-8 and 3 known members in
mice (mdr1a, mdr1b, and
mdr2).9-11 The transfection of complementary
DNA (cDNA) derived from MDR1, mdr1a, and
mdr1b confers multidrug resistance, but the transfection of
cDNA from MDR3 and mdr2 does
not.9,10,12-16
The MDR1 gene is expressed in both normal
tissues17 and malignancies.18,19 It is thus
important to understand how P-gp is specifically expressed in cancer
cells in order to use P-gp as a diagnostic marker for MDR in human
malignancies. Various mechanisms for MDR1 overexpression
have been reported in cultured cancer cell lines or tumor samples from
clinical patients. Gene amplification units of the MDR1 gene
have often been detected in cancer cells selected for their drug
resistance to multiple anticancer agents,20-24 but
amplification has not appeared in clinical samples. The MDR1
gene is activated through transcription factors NF-Y25 and Y-box binding protein (YB-1)26 in
the presence of exogenous stimuli including ultraviolet light,
irradiation, and carcinogens. Cellular translocation of YB-1 from
cytoplasm to nuclei has been shown to be closely associated with P-gp
expression in several cancers.27-29 The alteration of
methylation status at CpG sites on MDR1 gene promoters has
also been shown to be involved in MDR1 gene expression in
cultured cancer cell lines.22,30 Demethylation at CpG
sites on MDR1 gene promoters has also been closely
associated with P-gp expression in patients with acute myeloid
leukemias.31
Mickley et al32 have reported that gene rearrangement at
the 5'-flanking region of the MDR1 gene was responsible for
transcriptional activation of the MDR1 gene in
drug-resistant cell lines derived from colon and breast cancers. The
authors also showed rearrangement at the 5'-flanking region of
MDR1 in clinical samples of acute lymphoblastic leukemias.
This activation might be induced by read-through transcription from the
promoter of a fused, upstream-positioned gene. Determination of the
rearranged sequence indicated that the gene rearrangements occurred
from homologous recombination between Alu
repeats.33
As an alternative approach to understanding how the initial onset of
drug resistance in cancer cells appears during anticancer chemotreatment in vivo, an animal model could be useful to clarify the mechanism of overexpression of MDR genes.
Chemotherapeutic models consisting of animals carrying
transplanted cancer cells are expected to avoid the potential
heterogeneity of tumor cells in human clinical
samples.34-36 In this study we inoculated mouse leukemia
cells into the intraperitoneal cavity and treated the mice with
vincristine. We then examined the mechanisms involved in the appearance
of leukemia cells that were refractory to chemotherapeutic agents.
Based on these results, we discuss the appearance of P-gp-expressing leukemia cells in association with a novel type of gene rearrangement of the MDR gene by retroviral insertion.
Oligonucleotides
Cell lines and cell culture
Animals and in vivo chemotherapeutic models We used 5- to 6-week-old female CD2F1 mice (Charles River, Yokohama, Japan) and P388 murine leukemia cell lines (Human Science Research Resources Bank, Osaka, Japan). CD2F1 mice were inoculated in the abdomen with 1.0 × 106 P388 cells and derivatives.34,36 Mice in the vincristine treatment group were innoculated twice with 1 mg/kg interperitoneal vincristine, and mice in the control group were given saline. Survival of the mice was observed during the experimental period. The effectiveness of vincristine treatment was evaluated based on the mean survival days, which were analyzed by Student t test. P388 cells and derivatives were harvested from the tumor-carrying mice just before their death. Cells were suspended again in medium containing 1.0 × 106 cells and then transplanted to the next generation of mice. This cycle was repeated with 4 generations of mice.Isolation of DNA and RNA High-molecular-weight DNA23,37 and RNA30 were isolated as previously described.Semiquantitative reverse transcriptase-polymerase chain reaction The semiquantitative reverse transcriptase-polymerase chain reaction (RT-PCR) method was previously described.31,38 The template cDNA was diluted serially in water from 500 to 0.2 ng/µL. Each cycle of PCR included 30 seconds of denaturation at 94°C, 30 seconds of primer annealing at 55°C, and 30 seconds of polymerization at 72°C. We performed PCR with 35 cycles for mdr1a and 25 cycles for 2-microglobulin. The
PCR products were separated by electrophoresis on 3% agarose gels,
stained with CYBR green (Molecular Probes, Eugene, OR), and
image-analyzed by FAS 2000 (Fuji Photo Film, Tokyo, Japan).
Immunohistochemistry Immunohistochemistry was performed using ImmunoCruz Staining Systems (Santa Cruz Biotechnology, Santa Cruz, CA) including goat polyclonal anti-P-gp antibody (C-19) and biotinylated antigoat secondary antibody (both from Santa Cruz Biotechnology) according to the manufacturer's instruction.Southern blot analysis The genomic DNA was digested by either a methylation-insensitive or methylation-sensitive restriction enzyme, MspI or HpaII, respectively. The digested DNA was separated on a 2% agarose gel and transferred to nylon filters. We used 370-bp (base pair) PstI fragments of the mouse mdr1a promoter region located 100 bp upstream from the transcriptional start of mdr1a as probes.Vectorette PCR method The vectorette linkers were prepared by annealing 2 oligonucleotides, ts-oligo1 and bs-oligo. The ts-oligo was not complementary to the bs-oligo in the middle 30-bp region. MspI-digested genomic DNA from vincristine-resistant P-V4 cells were separated on agarose gel, and MspI fragments approximately 500 bp in length were isolated and ligated by the vectorette linkers. When PCR is performed with the primer uvp, which is complementary to bs-oligo but not to ts-oligo, and the mdr1a-specific primer, msp, the sequence between primers uvp and msp is amplified, but it is not amplified between 2 uvp primers. Additional details about the vectorette PCR method were described previously.39,40 The vectorette linkers were also used to analyze the MuLV proviral distribution in the host genome. The genomic DNA derived from P388 and vincristine-selected derivatives (P-V1, P-V2, P-V3, and P-V4), were digested by restriction enzymes NheI, SpeI, and XbaI. Although each of these 3 enzymes recognizes the different sites, they generate the same 5'-overhanged cohesive end, 5'-CTAG-3'. The vectorette linkers prepared by annealing ts-oligo2 and bs-oligo are compatible to this cohesive end. PCR was performed by using the primer uvp and the MuLV-specific primer musp1 at first, which was then nested by primer uvp and the second MuLV-specific primer musp2. The nested PCR products were analyzed by separation on 10% acrylamide gel electrophoresis.Luciferase reporter assay The MuLV long-terminal repeat (LTR)/mdr1a promoter sequence was amplified from genomic DNA of P-V4 cells by PCR using the primer pair pr-luciF and pr-luciR. The MuLV-mdr1a promoter hybrid fragments were ligated upstream of luciferase cDNA of pGL3-basic vector (Promega, Madison, WI) and designated as pGL3-L/m1a. We next made an LTR-deleted construct, named pGL3-m1a, by PstI digestion. The PstI-digested LTR fragment was cloned by SalI linker into the SalI site of pGL3-m1a, which is located downstream of luciferase, thereby generating pGL3-m1a/L. For transient transfection, NIH3T3 cells were cotransfected with 1 µg luciferase plasmid DNA and 20 ng pRL-CMV vector (Promega) by using LipofectAMINE 2000 (Gibco BRL Life Technologies, Rockville, MD) according to the manufacturer's instructions. The measurement of luciferase activity of transient transfectants was performed using a dual-luciferase assay protocol (Promega).PCR to detect the existence of rearranged genomes We used 10 µg genomic DNA, which was equivalent to 1.0 × 106 cells, as templates to amplify the rearranged MuLV LTR/mdr1a sequences by PCR with primers pr-ltr/1aF and pr-ltr/1aR. The PCR product was subcloned (pCR-L/m1a) and used as a template as follows. In the control experiment, 10 µg genomic DNA of mouse fibroblast L cells containing the serially diluted pCR-L/m1a from 3.3 pg (106 copies) to 3.3 × 10 6 pg (one
copy) was used as template. PCR was performed with AmpliTaq Gold DNA
polymerase (PE Applied Biosystems, Urayasu, Japan). Each cycle of PCR
included 30 seconds of denaturation at 94°C, 30 seconds of primer
annealing at 58°C, and 45 seconds of polymerization at 72°C. PCR
was performed with 45 cycles and repeated again using the first PCR
product as template.
Appearance of leukemia cells refractory to chemotherapeutic treatment with vincristine We used the mice carrying P388 murine leukemia cells as a chemotherapeutic model to investigate the molecular basis for the acquisition of MDR in vivo. We transplanted leukemia cells into the abdominal cavity of mice and continuously treated the mice with vincristine at each transplantation step (Figure 1A). To assess the therapeutic efficacy of vincristine, we examined the life span of mice at each transplanted step (Figure 1B). The life span of mice treated with vincristine was prolonged by 13-15 days up to the second serial transplantation (early-transplantation mice); mice without any treatment died within 10-12 days after transplantation of leukemia cells (Figure 1B). By contrast, the life spans of mice became shorter with each sequential transplantation and repetition of vincristine treatment. After 3 or 4 transplantations (later-transplantation mice), the life spans plateaued at 10 days, which corresponds to the life spans of untreated control mice, in spite of vincristine treatment. This result suggested the appearance of drug-resistant leukemia cells in later-transplantation mice. It is also noted that this result was highly reproducible in the second experiment (data not shown).
Overexpression of the mdr1a gene in vincristine-treated leukemia cells Because the mdr1a, mdr1b, and mrp41 genes are often highly expressed in cancer cells exposed to Vinca alkaloids, we next examined the expression of these genes by semiquantitative RT-PCR method (Figure 2A). We could not find any significant increase in the level of mdr1b or mrp messenger RNA (mRNA) of the leukemia cells during repeated treatments with vincristine (data not shown). Only the level of mdr1a mRNA was elevated in vincristine-resistant cells (P-V2, P-V3, and P-V4) in comparison to controls (Figure 2B). Parental P388 cells did not show any expression of mdr1a. P-V2 cells collected after the second transplantation with vincristine treatment showed a significant increase in mdr1a expression compared with parental cells. After later transplantations, P-V4 cells showed further increases in mdr1a expression, and a clear correlation between the increase of mdr1a expression and the decrease of the life span of mice was observed. Overexpression of the mdr1a gene was also detected by immunohistochemistry during transplantations in P-V2, P-V3 (data not shown), and P-V4 cells (Figure 3).
Gene rearrangement at the mdr1a promoter region in leukemia cells that are refractory to vincristine To identify the molecular mechanisms involved in up-regulation of mdr1a expression, we first examined the gene amplification and methylation status of the promoter region of mdr1a by Southern blot analysis. As shown in Figure 4A, there was no change in the intensity of 2 850- and 216-bp (base pair)-long bands among all samples, which suggests that the mdr1a gene was not amplified during vincristine treatment. We next examined the methylation status by digestion with a methylation-sensitive restriction endonuclease, HpaII. We detected 216-bp fragments and bands with higher molecular weight in all samples, but we did not detect change in intensity of those bands (Figure 4B), suggesting hypermethylation at the HpaII site a and hypomethylation at both site b and c (Figure 4C). This suggested that there was no alteration of methylation status during vincristine treatment. On the other hand, we detected extra fragments of 500 bp in the lanes derived from P-V2, P-V3, and P-V4 when digested with either MspI or HpaII (Figure 4A,B). We hypothesized that the extra fragments representing the gene rearrangement occurred upstream of the mdr1a promoter region in these cells. It should be noted that these cells also showed a relatively high mdr1a expression (Figure 2), suggesting that the rearrangement might be responsible for overexpression of the mdr1a gene.
Characterization of the rearranged sequence We next determined the junction sequence and molecular nature of the mdr1a gene rearrangement. We used a vectorette construct for selective amplification of the 500-bp MspI fragment. Subcloning and nucleotide sequence analysis revealed that the extra fragment actually consisted of 484 bp, including 355 bp of the mdr1a sequence and a 129-bp sequence identical to the minus strand of the 5' LTR of MuLV (Figure 5). The nucleotide sequence corresponding to the MspI/HpaII recognition site at the LTR is consistent with the generation of the 500-bp fragment by MspI/HpaII digestion from genomic DNA isolated from P-V2 to V4. These data suggested that the rearrangement resulted from the insertion of the MuLV genome into the promoter region of the mdr1a gene. Southern blot analysis and sequencing of the junction between the region further upstream of the mdr1a and the 3' LTR confirmed this possibility (data not shown). It is noted that we detected exactly the same junction sequence when we repeated the in vivo chemotreatment protocol.
Characterization of the mdr1a mRNA product overexpressed in leukemia cells refractory to vincristine We analyzed the mdr1a mRNA by RT-PCR methods using 2 pairs of primers pr-ltr/1aF and pr-ltr/1aR, and pr-1a3'F and
pr-1a3'Rthat amplify the sequence derived from possible
LTR/mdr1a hybrid mRNA and the normal transcript of
mdr1a, respectively. The mdr1a transcriptional products could be detected in LV500, P-V2,
P-V3, and P-V4 cells but not in parental P388
cells (Figure 6A). However, only normal transcripts existed in these cells. Hybrid mRNA, which was expected to
be generated if the LTR would act as an upstream-located promoter of
mdr1a transcription, could not be detected in any of the
above cells (Figure 6B).
The MuLV LTR sequence shows positive enhancer activity to mdr1a promoter We isolated the rearranged promoter region and examined whether the MuLV LTR sequence could activate the mdr1a gene by luciferase-reporter assay (Figure 7). We found that the LTR sequence increased the luciferase activity when it was positioned either upstream (pGL3-L/m1a) or downstream (pGL3-m1a/L) of mdr1a promoter-luciferase. Transfection of either pGL3-L/m1a or pGL3-m1a/L to NIH3T3 cells resulted in a 70- to 80-fold increase in luciferase activity relative to that resulting from transfection of the pGL3-basic vector. Next, we demonstrated that deletion of the LTR sequence drastically decreased the level of luciferase activity. The LTR-deleted construct pGL-m1a showed less luciferase activity, about one-fifth of the activity of pGL3-L/m1a and pGL3-m1a/L. These results strongly supported the idea that the opposite-directed MuLV LTR up-regulates the transcription of the mdr1a gene as a positive enhancer.
Detection of an MuLV LTR/mdrla rearranged genomic sequence in leukemia cells It remains unclear whether the cell populations that primarily contain the rearranged sequence were selected by repeated vincristine treatment or the gene rearrangement was induced by MuLV insertion during the treatment. We thus examined whether the rearranged sequence existed primarily in the initial inoculums by PCR assay using genomic DNA of P388 and its derivatives as templates and LTR- and mdr1a-specific primers (Figure 8A). We used 10 µg genomic DNA as a template, which was equivalent to 1.0 × 106 cells and to the initial inoculum. We could detect the amplified products in vincristine-treated derivatives P-V2, P-V3, and P-V4, but not in parental P388 or P-V1 cells (Figure 8A). In the control experiment, 10 µg genomic DNA of mouse fibroblast L cells containing the rearranged genomic DNA, which had been cloned into plasmid and serially diluted, was used as a template. The PCR product was detected even when one copy of the rearranged sequence was contained in the template (Figure 8B), suggesting that the PCR assay was sensitive enough to detect at least one copy of the rearranged sequence among genomic DNA equivalent to 1 × 106 cells.
Alteration of the distribution of proviral MuLV during vincristine treatment We hypothesized that the proviral MuLV was excised and integrated into the promoter region of the mdr1a gene during chemotreatment, probably by vincristine. We then examined whether the vincristine treatment could alter the distribution of the MuLV proviral genome. The experiment using a short-term culture of P388 in vitro failed, probably because the P388 cells, which had been maintained in vivo, have less viability in vitro. We then analyzed the MuLV distribution in the P388 derivatives by vectorette PCR (Figure 9A). Although the number of bands detected was similar among the parental P388, P-V1, P-V2, P-V3, and P-V4 cells (Figure 9B, represented by sharp signs and asterisks), novel specific bands (arrows) were detected in P-V1, P-V2, P-V3, and P-V4 cells but not in parental P388 cells. This suggests that vincristine treatment might induce the excision and integration of proviral MuLV. By contrast, only a few bands were generated in mouse fibroblast L cells (Figure 9B, asterisks), suggesting that L cells might have fewer copies of MuLV than P388 leukemia cells. Similar but distinct patterns of the altered MuLV distribution were observed in the second independent experiment (data not shown). This result further suggested that the random integration of MuLV might be caused during these 2 independent experiments of vincristine chemotreatment.
We examined the molecular basis for mdr1a overexpression in leukemia cells during continuous treatment with vincristine. The therapeutic model we used has 2 advantages over analysis of human clinical samples: (1) the inoculated tumor is basically monoclonal, and (2) samples are available at every step during the clinical course. The therapeutic effect by vincristine on mice carrying the leukemia cells was abolished during repeated treatment, accompanying overexpression of mdr1a mRNA. Previous studies have reported that demethylation of the CpG sites at the promoter region was inversely correlated with human MDR1 overexpression both in vitro and in vivo.30,31,42 In the present study, however, no alteration in the methylation status of CpG sites occurred in any of the P388 derivatives, irrespective of whether or not mdr1a expression was observed. CpG methylation thus may not be responsible for the regulation of mdr1a expression in our experimental system. Integration of MuLV was observed at the mdr1a promoter region in leukemia cells when expression of mdr1a was enhanced. This raises the question of whether or not the MuLV integration is associated with mdr1a overexpression. Overexpression of mdr1a mRNA could be induced by transcription that started from the LTR promoter through the mdr1a gene. However, the transcriptional direction of the LTR promoter is opposite that of mdr1a, and no chimerical mRNA of mdr1a fused to the MuLV LTR was found. Payne et al43 have previously reported that retroviral 5' LTR, which is inserted inverse to the transcriptional direction of the c-myc gene located downstream, enhances the transcription of the gene. Using a luciferase assay, we here demonstrated that insertion of the LTR of MuLV into the mdr1a promoter region enhances the gene transcription irrespective of the position of the LTR. MuLV insertion could act as an enhancer element to activate the mdr1a gene. Although MuLV insertion at the mdr1a gene in vivo has not been reported so far, a similar observation in vitro has been reported. Lepage et al44 reported the insertion of a murine mammary tumor virus and intracisternal A-particle at the mdr1a promoter region in vincristine- and adriamycin-resistant P388 leukemia cells, respectively. Both of the integration sites and viruses reported by the authors44 are different from those identified in our study. Infection of mouse bone marrow cells with retroviral vectors, followed by treatment with taxol, a P-gp-targeting agent, also efficiently enhanced integration of the retrovirus into mdr1a and mdr1b gene promoters (Y. Sugimoto and T. Tsuruo, personal communication, October 1999). In our present study, however, we could not observe any apparent increase in mdr1b expression. Treatment with P-gp-targeting drugs appears to rather specifically induce up-regulation of MDR-related genes through the insertion of retroviruses. These previous reports and our present in vivo study suggest that retroviral transposons may prefer to integrate into the mdr1a promoter region. Although there is no obvious sequence similarity among the integration sites, some type of preferential DNA or chromatin structure for retroviral integration in these promoter regions may exist. The association between the virus integration and mdr1a overexpression during chemotreatment may be attributable to either of 2 mechanisms: (1) de novo insertion of MuLV induced by vincristine treatment or (2) selection of a small fraction of pre-existing cells carrying MuLV insertion during vincristine treatment. We could not detect the rearranged genomic DNA in the parental cells by PCR assay, and we found the alteration of proviral MuLV distribution during chemotreatment. These data might suggest the possibility of de novo insertion. Alternatively, the same integration sites of the virus at the mdr1a promoter were identified in 2 independent experiments with the same therapeutic protocol. This finding would seem to suggest the second mechanism. The alteration of MuLV distribution might reflect the selection of leukemia cells, which intrinsically carried the altered pattern of MuLV distribution. Thus, based on these results, we were unable to determine which of the above mechanisms was more likely. Whatever the precise mechanism is, it should be noted that in vivo chemotreatment using vincristine could induce generation of mdr1a-overexpressing cells through retrovirus insertion and the enhancer effect of LTR. Concerning the plausible mechanism for MuLV insertion into the mdr1a gene, DNA damaging agents often activate transposable elements in genomes and induce gene rearrangement. For example, Ty retrotransposons can be activated by ultraviolet light in yeast.45 Tanaka and Ishihara46 also reported radiation-induced intracisternal A-particle integration in mouse myeloid leukemia cell strains. Vincristine treatment is reported to generate oxiradicals,47 and enhancement of the viral integration by oxidative stress has also been reported.48 The retroviral integration might be enhanced by vincristine-induced oxidative stress, but the details have not yet been clarified. Gene rearrangements, associated with human MDR1 gene overexpression, have been observed in cultured multidrug-resistant cell lines and in clinical samples.32,49 Such drug-resistant human cancer cell lines express hybrid mRNAs containing sequences from both MDR1 and unrelated genes located upstream. We have recently reported Alu repeats near the junction sequence in these MDR cancer cell lines.33 The genomic instability intrinsic in malignant cancer cells also appears to modulate MDR gene expression. Further studies are now in progress to determine whether the human MDR1 gene can be activated by retroviral integration in clinical specimens of human hematopoietic malignancies that are refractory to chemotherapeutic agents.
We thank Dr Kathleen W. Scotto (Memorial Sloan-Kettering Cancer Center, New York, NY), Dr Igor B. Roninson (University of Illinois, Urbana), and Dr Kimitoshi Kohno (University of Occupational and Environmental Health, Kitakyushu, Japan) for fruitful discussion. We also thank Dr Yoshikazu Sugimoto (Japanese Foundation for Cancer Research) and Dr Takashi Tsuruo (The University of Tokyo, Japan) for providing important information.
Submitted January 13, 2000; accepted October 4, 2000.
Supported by a grant from the Ministry of Education, Science, Sports, and Culture of Japan (11694286); a grant from the Second-Term Comprehensive 10-Year Strategy for Cancer Control from the Ministry of Health and Welfare (H12gan011); and a grant from Core Research for Evolutional Science and Technology (CREST) of Japan Science and Technology Corporation (JST), Tokyo.
The publication costs of this article were defrayed in part by page charge payment. Therefore, and solely to indicate this fact, this article is hereby marked "advertisement" in accordance with 18 U.S.C. section 1734.
Reprints: Morimasa Wada, Department of Medical Biochemistry, Graduate School of Medical Sciences, Kyushu University, 3-1-1 Maidashi Higashi-ku, Fukuoka, 812-8582, Japan; e-mail: wada{at}biochem1.med.kyushu-u.ac.jp.
1. Bradley G, Juranka PF, Ling V. Mechanism of multidrug resistance. Biochim Biophys Acta. 1988;948:87-128[Medline] [Order article via Infotrieve]. 2. Pastan I, Gottesman M. Multiple-drug resistance in human cancer. N Engl J Med. 1987;316:1388-1393[Medline] [Order article via Infotrieve]. 3. van der Bliek AM, Borst P. Multidrug resistance. Adv Cancer Res. 1989;52:165-203[Medline] [Order article via Infotrieve]. 4. Leith C. Multidrug resistance in leukemia. Curr Opin Hematol. 1998;5:287-291[Medline] [Order article via Infotrieve]. 5. List AF. Multidrug resistance: clinical relevance in acute leukemia [review]. Oncology. 1993;7:23-28[Medline] [Order article via Infotrieve]32; discussion 32, 35-38. 6. List AF, Spier CM. Multidrug resistance in acute leukemia: a conserved physiologic function. Leuk Lymphoma. 1992;8:9-14[Medline] [Order article via Infotrieve].
7.
Chin JE, Soffir R, Noonan KE, Choi K, Roninson IB.
Structure and expression of the human MDR (P-glycoprotein) gene family.
Mol Cell Biol.
1989;9:3808-3820
8.
Roninson IB, Chin JE, Choi KG, et al.
Isolation of human mdr DNA sequences amplified in multidrug-resistant KB carcinoma cells.
Proc Natl Acad Sci U S A.
1986;83:4538-4542
9.
Devault A, Gros P.
Two members of the mouse mdr gene family confer multidrug resistance with overlapping but distinct drug specificities.
Mol Cell Biol.
1990;10:1652-1663 10. Gros P, Ben Neriah YB, Croop JM, Housman DE. Isolation and expression of a complementary DNA that confers multidrug resistance. Nature. 1986;323:728-731[CrossRef][Medline] [Order article via Infotrieve].
11.
Gros P, Raymond M, Bell J, Housman D.
Cloning and characterization of a second member of the mouse mdr gene family.
Mol Cell Biol.
1988;8:2770-2778
12.
Lincke CR, van der Bliek AM, Schuurhuis GJ, et al.
Multidrug resistance phenotype of human BRO melanoma cells transfected with a wild-type human mdr1 complementary DNA.
Cancer Res.
1990;50:1779-1785
13.
Hsu SI, Lothstein L, Horwitz SB.
Differential overexpression of three mdr gene family members in multidrug-resistant J774.2 mouse cells: evidence that distinct P- glycoprotein precursors are encoded by unique mdr genes.
J Biol Chem.
1989;264:12053-12062
14.
Schinkel AH, Roelofs EM, Borst P.
Characterization of the human MDR3 P-glycoprotein and its recognition by P-glycoprotein-specific monoclonal antibodies.
Cancer Res.
1991;51:2628-2635
15.
Ueda K, Cardarelli C, Gottesman MM, Pastan I.
Expression of a full-length cDNA for the human "MDR1" gene confers resistance to colchicine, doxorubicin, and vinblastine.
Proc Natl Acad Sci U S A.
1987;84:3004-3008 16. van der Bliek AM, Kooiman PM, Schneider C, Borst P. Sequence of mdr3 cDNA encoding a human P-glycoprotein. Gene. 1988;71:401-411[CrossRef][Medline] [Order article via Infotrieve]. 17. Chen CJ, Chin JE, Ueda K, et al. Internal duplication and homology with bacterial transport proteins in the mdr1 (P-glycoprotein) gene from multidrug-resistant human cells. Cell. 1986;47:381-389[CrossRef][Medline] [Order article via Infotrieve].
18.
Goldstein LJ, Galski H, Fojo A, et al.
Expression of a multidrug resistance gene in human cancers.
J Natl Cancer Inst.
1989;81:116-124 19. Nooter K, Sonneveld P, Oostrum R, et al. Overexpression of the mdr1 gene in blast cells from patients with acute myelocytic leukemia is associated with decreased anthracycline accumulation that can be restored by cyclosporin-A. Int J Cancer. 1990;45:263-268[Medline] [Order article via Infotrieve].
20.
Fojo AT, Whang-Peng J, Gottesman MM, Pastan I.
Amplification of DNA sequences in human multidrug-resistant KB carcinoma cells.
Proc Natl Acad Sci U S A.
1985;82:7661-7665
21.
Scotto KW, Biedler JL, Melera PW.
Amplification and expression of genes associated with multidrug resistance in mammalian cells.
Science.
1986;232:751-755 22. Kusaba H, Nakayama M, Harada T, et al. Maintenance of hypomethylation status and preferential expression of exogenous human MDR1/PGY1 gene in mouse L cells by YAC mediated transfer. Somat Cell Mol Genet. 1997;23:259-274[Medline] [Order article via Infotrieve].
23.
Torigoe K, Sato S, Kusaba H, et al.
A YAC-based contig of 1.5 Mb spanning the human multidrug resistance gene region and delineating the amplification unit in three human multidrug-resistant cell lines.
Genome Res.
1995;5:233-244 24. Torigoe K, Harada T, Kusaba H, et al. Localization of 67 exons on a YAC contig spanning 1.5 Mb around the multidrug resistance gene region of human chromosome 7q21.1. Genomics. 1998;49:14-22[CrossRef][Medline] [Order article via Infotrieve].
25.
Jin S, Scotto KW.
Transcriptional regulation of the MDR1 gene by histone acetyltransferase and deacetylase is mediated by NF-Y.
Mol Cell Biol.
1998;18:4377-4384
26.
Ohga T, Uchiumi T, Makino Y, et al.
Direct involvement of the Y-box binding protein YB-1 in genotoxic stress-induced activation of the human multidrug resistance 1 gene.
J Biol Chem.
1998;273:5997-6000 27. Bargou RC, Jurchott K, Wagener C, et al. Nuclear localization and increased levels of transcription factor YB-1 in primary human breast cancers are associated with intrinsic MDR1 gene expression. Nat Med. 1997;3:447-450[CrossRef][Medline] [Order article via Infotrieve]. 28. Oda Y, Sakamoto A, Shinohara N, et al. Nuclear expression of YB-1 protein correlates with P-glycoprotein expression in human osteosarcoma. Clin Cancer Res. 1998;4:2273-2277[Abstract]. 29. Kamura T, Yahata H, Amada S, et al. Is nuclear expression of Y box-binding protein-1 a new prognostic factor in ovarian serous adenocarcinoma? Cancer. 1999;85:2450-2454[CrossRef][Medline] [Order article via Infotrieve]. 30. Kusaba H, Nakayama M, Harada T, et al. Association of 5' CpG demethylation and altered chromatin structure in the promoter region with transcriptional activation of the multidrug resistance 1 gene in human cancer cells. Eur J Biochem. 1999;262:924-932[Medline] [Order article via Infotrieve].
31.
Nakayama M, Wada M, Harada T, et al.
Hypomethylation status of CpG sites at the promoter region and overexpression of the human MDR1 gene in acute myeloid leukemias.
Blood.
1998;92:4296-4307 32. Mickley LA, Spengler BA, Knutsen TA, Biedler JL, Fojo T. Gene rearrangement: a novel mechanism for MDR-1 gene activation. J Clin Invest. 1997;99:1947-1957[Medline] [Order article via Infotrieve]. 33. Harada T, Nagayama J, Kohno K, et al. Alu-associated interstitial deletions and chromosomal re-arrangement in 2 human multidrug-resistant cell lines. Int J Cancer. 2000;86:506-511[CrossRef][Medline] [Order article via Infotrieve]. 34. Kiue A, Sano T, Naito A, et al. Enhancement of antitumour activity of etoposide by dihydropyridines on drug-sensitive and drug-resistant leukaemia in mice. Br J Cancer. 1991;64:221-226[Medline] [Order article via Infotrieve].
35.
Yang JM, Goldenberg S, Gottesman MM, Hait WN.
Characteristics of P388/VMDRC.04, a simple, sensitive model for studying P-glycoprotein antagonists.
Cancer Res.
1994;54:730-737
36.
Kiue A, Sano T, Suzuki K, et al.
Activities of newly synthesized dihydropyridines in overcoming of vincristine resistance, calcium antagonism, and inhibition of photoaffinity labeling of P-glycoprotein in rodents.
Cancer Res.
1990;50:310-317
37.
Kusaba H, Kohno K, Asakuno K, et al.
Functional expression of yeast artificial chromosome-human multidrug resistance genes in mouse cells.
Genome Res.
1995;5:245-258 38. Noonan KE, Beck C, Holzmayer TA, et al. Quantitative analysis of MDR1 (multidrug resistance) gene expression in human tumors by polymerase chain reaction. Proc Natl Acad Sci U S A. 1990;87:7160-7164 |
Top
Abstract
Introduction
, C). The physical maps of the mdr1a
5'-flanking region without rearrangement (upper) and with putative
rearrangement (lower) are presented in panel C. The open box and
horizontal arrow correspond to mdr1a exon-1 and its
transcriptional direction, respectively. Vertical arrows indicate
MspI/HpaII sites. In the lower map the broken
line represents the putative rearranged DNA, and the expected
MspI/HpaII site is indicated as site a'. The
restriction patterns of HpaII suggested that site a was
hypermethylated, and both sites b and c were hypomethylated.
